eukaryotic translation initiation factor 4E pseudogene 3Genealiases: []
Q-omics provides the consensus-scored EIF4EP3 profile across patient tissues and cancer cell-line models. EIF4EP3 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, EIF4EP3 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, EIF4EP3 RNA expression shows 8,690 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, THCA, and LSCC as cancer lineages where EIF4EP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4EP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4EP3 survival associations across molecular data types. EIF4EP3 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4EP3 RNA expression–survival associations across cancer types. High EIF4EP3 expression shows unfavorable associations in PAAD, ACC, LUSC, THCA and BLCA, but favorable associations in CESC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for EIF4EP3 RNA expression.
This table summarizes EIF4EP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4EP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4EP3 shows lower tumor expression in THCA and higher tumor expression in HNSC, PRAD and BRCA. The THCA box plot shows higher EIF4EP3 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p = .008).
This table shows molecular features associated with EIF4EP3 in patient tissues and cancer cell lines. In patient samples, EIF4EP3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
